EcoDrugPlus

Membrane Primary Amine Oxidase-Like

Ensembl ID : ENSCPRG00005008209
Gene Symbol: LOC109320387
2 Cross references
358 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Membrane Primary Amine Oxidase-Like

Ensembl ID : ENSCPRG00005017646
Gene Symbol: LOC109306908
2 Cross references
350 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Methionyl Aminopeptidase 2

Ensembl ID : ENSCPRG00005019100
Gene Symbol: METAP2
3 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Microtubule Associated Protein Tau

Ensembl ID : ENSCPRG00005008071
Gene Symbol: MAPT
3 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSCPRG00005000650
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCPRG00005013428
Gene Symbol: MAPK10
3 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSCPRG00005011004
Gene Symbol: MAPK11
3 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSCPRG00005003095
Gene Symbol: MAPK14
3 Cross references
295 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSCPRG00005017980
Gene Symbol: MAPK8
3 Cross references
293 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSCPRG00005011481
Gene Symbol: MAPK9
3 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSCPRG00005000623
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSCPRG00005008753
Gene Symbol: MAP2K2
3 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).